O Shaughnessy Asset Management LLC Boosts Stock Holdings in CVS Health Corporation $CVS

O Shaughnessy Asset Management LLC boosted its stake in shares of CVS Health Corporation (NYSE:CVS) by 14.3% in the 4th quarter, HoldingsChannel reports. The fund owned 259,380 shares of the pharmacy operator’s stock after buying an additional 32,536 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in CVS Health were worth $20,584,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of CVS Health during the fourth quarter valued at about $1,666,265,000. Wellington Management Group LLP increased its holdings in CVS Health by 391.6% during the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after purchasing an additional 5,042,816 shares during the period. Amundi raised its position in CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares during the last quarter. Capital Research Global Investors lifted its holdings in CVS Health by 24.5% in the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after buying an additional 2,253,531 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of CVS Health by 70.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after buying an additional 2,188,307 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: UBS Group raised its price target on CVS Health to $115 from $100 and kept a Buy rating, signaling greater confidence in the company’s upside. MarketScreener
• Positive Sentiment: Truist also lifted its price objective on CVS to $108 from $102 and reiterated a Buy rating, adding to the bullish analyst momentum. Yahoo Finance
• Positive Sentiment: Several reports highlighted CVS as an attractive value/blue-chip name under $100, which can support investor interest in the stock. Yahoo Finance
• Neutral Sentiment: CVS published a company update about helping Medicare members improve access to care through its health coach and social-risk support programs, reinforcing its care-management strategy but not likely to move the stock on its own. Yahoo Finance
• Neutral Sentiment: Coverage on CVS outperforming other medical stocks this year, along with broader articles on Medicare Advantage growth, suggests the business is benefiting from favorable sector trends. Zacks
• Neutral Sentiment: CVS chief David Joyner defended the company’s partnership with Mass General Brigham to expand primary care in stores, a strategic initiative that could help long-term growth but is not an immediate earnings catalyst. Boston Globe
• Negative Sentiment: No major negative headline surfaced in the last day; the main risk is that the recent run-up in CVS may leave the stock more sensitive to any future disappointment in healthcare margins or guidance.

Insider Activity

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last quarter. 0.85% of the stock is owned by corporate insiders.

CVS Health Trading Up 1.2%

Shares of NYSE CVS opened at $97.08 on Tuesday. The company has a market cap of $123.87 billion, a PE ratio of 42.77, a P/E/G ratio of 0.94 and a beta of 0.62. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm’s 50 day moving average price is $84.65 and its 200-day moving average price is $80.17. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $98.43.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same period in the previous year, the business earned $2.25 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.7%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Analyst Ratings Changes

A number of analysts recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $113.00 price target on shares of CVS Health in a research note on Monday, June 1st. Sanford C. Bernstein raised their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Truist Financial boosted their price target on shares of CVS Health from $102.00 to $108.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Robert W. Baird increased their price target on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Finally, Mizuho raised their price objective on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and a consensus target price of $100.68.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.